|1.||Henderson-Smart, D J: 5 articles (01/2001 - 01/2000)|
|2.||Gorman, Jack M: 4 articles (05/2015 - 05/2003)|
|3.||Martinez, Jose M: 3 articles (05/2015 - 07/2005)|
|4.||Boutroy, M J: 3 articles (02/2005 - 11/2000)|
|5.||Steer, P: 3 articles (01/2004 - 01/2000)|
|6.||Aaronson, Cindy J: 2 articles (05/2015 - 10/2007)|
|7.||Garakani, Amir: 2 articles (05/2015 - 10/2007)|
|8.||Yamazaki, Toshio: 2 articles (04/2015 - 01/2007)|
|9.||Ishitsuka, Yoichi: 2 articles (04/2015 - 06/2013)|
|10.||Irikura, Mitsuru: 2 articles (04/2015 - 06/2013)|
01/01/1992 - "Data suggested that doxapram alone at a dose of 1 mg/kg/h is effective for the treatment of neonatal apnea."
08/01/1991 - "The efficacy of low-dose doxapram therapy (0.2 mg/kg/h) in combination with methylxanthines was evaluated in 20 premature infants with idiopathic apnea unresponsive to methylxanthines alone, and in 13 premature infants with secondary apnea. "
01/01/2007 - "Recent studies, however, have demonstrated the efficacy and safety of doxapram therapy for apnea of prematurity (AOP) using lower doses than those previously tested. "
01/01/2004 - "All trials utilising random or quasi-random patient allocation, in which doxapram was used for the treatment of apnea in preterm infants were included. "
04/01/2001 - "However, because of encouraging results of recent studies regarding the efficacy and safety of therapy for apnea of prematurity (AOP) with lower doses of doxapram than those previously proposed, approximately 60% of Japanese neonatologists continue to use doxapram at small doses. "
|2.||Respiratory Insufficiency (Respiratory Failure)
01/01/1975 - "Protection against the risk of occasional respiratory depression from this regime is consistently given by the use of intravenous doxapram, which also gives varying degrees of arousal."
02/01/1979 - "The respiratory stimulant drug doxapram has overcome respiratory depression in volunteers and in a few patients in a clinical setting, but such studies have not been done in an overdose situation. "
12/04/1989 - "[Doxapram therapy in acute progressive chronic respiratory failure]."
07/10/1989 - "Only minor side-effects from doxapram were observed, and it is concluded that this respiratory stimulant can be used as a primary drug in patients with acute respiratory failure and chronic airflow limitation."
07/10/1989 - "[A pharmacologic respiratory stimulant, doxapram, used in acute deterioration in patients with chronic respiratory failure]."
|3.||Body Weight (Weight, Body)
02/01/1979 - "In 6 separate trials at a dose range of 0.32 to 2.0 mg per kg of body weight per min, quiet-sleep tidal volume increased from 4.9 +/- 1.0 to 8.5 +/- 0.9 ml per kg of body weight, minute ventilation increased from 140 +/- 38 to 286 +/- 31 ml per kg of body weight per min, and alveolar PCO2 decreased from 60 +/- 5 to 32 +/- 2 mm Hg. In all instances, the maximal quiet-sleep ventilatory response was achieved within 10 min. The ventilatory response to steady-state CO2 breathing was not improved with doxapram. "
04/01/2015 - "Estimates generated by NONMEM indicated that clearance of doxapram (CL; L/kg/h) was affected by postmenstrual age (PMA; weeks), body weight (BW; g), and aspartate aminotransferase (AST; IU/L). "
01/01/1992 - "Two treatments, sodium bicarbonate (3 mEq/kg of body weight, IV) and doxapram HCl (2 mg/kg, IV), were evaluated, using a randomized complete-block experimental design. "
11/01/1977 - "Rapid arousal from the sedative effects of xylazine occurred after the intravenous administration of doxapram hydrochloride in dosages of 0.05 to 0.13 mg/kg of body weight."
11/01/1986 - "For each of 3 separate evaluations, 6 fasted llamas (Lama glama) were sedated with xylazine (1.1 mg/kg of body weight, IV) and then 15 minutes later were given normal saline solution (5.0 ml, IV; control values), doxapram (2.2 mg/kg, IV), or 4-amino-pyridine (0.3 mg/kg, IV) and yohimbine (0.125 mg/kg, IV). "
05/12/2005 - "Although, doxapram had an additive effect on the carotid body chemosensory response to hypercapnia, a synergistic effect was not observed. "
10/01/1994 - "We report three cases in which doxapram hydrochloride injection was used as an additional method of treating and stabilizing patients with chronic hypercapnia and hypoxia. "
10/01/1994 - "Use of doxapram hydrochloride injection as an alternative to intubation to treat chronic obstructive pulmonary disease patients with hypercapnia."
01/01/1989 - "[Effects of doxapram on the response to hypercapnia: application to weaning from artificial ventilation in chronic obstructive respiratory insufficiency]."
05/01/1982 - "However, the ventilatory effect of doxapram was more than additive to the concomitant stimulation by hypoxia or hypercapnia. "
10/01/1999 - "Doxapram resulted in a significant decrease in the frequency of apnoea [22 (11-27) vs. 14 (7-23)/h, p < 0.01], bradycardia [3 (0-7) vs. 1 (0-3)/h, p < 0.01] and hypoxaemia [8 (0-18) vs. 2 (0- 17)/h, p < 0.01] already after 1 day of treatment, which was sustained throughout the 6-day study period. "
10/01/1999 - "To study the effect of doxapram on the frequency of apnoea, bradycardia and hypoxaemia. "
10/01/1999 - "Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants."
05/01/1993 - "Despite this treatment, he underwent many episodes of apnea, and bradycardia that appeared on day 4 and did not respond to IV doxapram (1 mg/kg/h). "
10/01/1999 - "Doxapram substantially reduced the frequency of apnoea, bradycardia and hypoxaemia in these patients with caffeine-resistant apnoea of prematurity. "
|2.||Caffeine (No Doz)
|8.||Aspartate Aminotransferases (Aspartate Transaminase)
|9.||Doxapram (Doxapram Hydrochloride)
|10.||Morphine (MS Contin)
|2.||Intermittent Positive-Pressure Ventilation
|3.||Artificial Respiration (Mechanical Ventilation)
|4.||Mechanical Ventilators (Ventilator)